ADRA2C and glioblastoma: Compared with the control group, in both GL261 and U87 cells, the migration speed increased in the group treated with the ADRA2C antagonist, phentolamine, while it decreased in the group treated with the ADRA2C agonist, norepinephrine (Figure 11), suggesting that a lower ADRA2C expression level may promote the GBM cell migration.